Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
07:00am, Wednesday, 04'th Sep 2024
- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 - - Appointment strengthens leadership team as Company app
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
05:35pm, Thursday, 29'th Aug 2024
EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boos
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 27'th Aug 2024
WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Friday, 16'th Aug 2024
WATERTOWN, Mass., Aug. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
07:00am, Thursday, 08'th Aug 2024
WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
09:16am, Wednesday, 07'th Aug 2024
EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.61 per share a year ago.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Tuesday, 16'th Jul 2024
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
07:00am, Tuesday, 18'th Jun 2024
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 17'th Jun 2024
WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
07:00am, Wednesday, 05'th Jun 2024
WATERTOWN, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patie
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 16'th May 2024
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patien
Notable Insider Buying at Disney and More This Week
09:15am, Sunday, 12'th May 2024
The first full week of May did not bring more notable insider purchases from Warren Buffett.
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 08'th May 2024
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU ™ in wet AMD in 2H 2024 –
EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program
12:50pm, Tuesday, 07'th May 2024
Despite NPDR primary endpoint miss, potential exists with EyePoint Pharmaceuticals releasing 12-month phase 2 PAVIA data; potential for continued advancement depending upon data. LUGANO and LUCIA are
EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal
09:10am, Monday, 06'th May 2024
Shares of EyePoint Pharmaceuticals Inc. EYPT, -1.00% dropped nearly 30% in premarket trading Monday after the company said its experimental retinal-disease treatment had failed to meet the primary goa
